Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status

被引:19
作者
Giraldo, Pilar [1 ,2 ]
Perez-Lopez, Jordi [3 ]
Nunez, Ramiro [4 ]
Fernandez de la Puebla, Rafael [5 ]
Luno, Elisa [6 ]
Saura-Grau, Salvador [7 ]
Carlos Bureo, Juan [8 ]
Plaza, Sylvia [9 ]
de la Serna, Javier [10 ]
机构
[1] Miguel Servet Univ Hosp, Translat Res Unit, IIS Aragon, CIBER Enfermedades Raras CIBERER,Aragon Inst Hlth, Zaragoza, Spain
[2] Spanish Fdn Study & Therapy Gaucher Dis FEETEG, Zaragoza, Spain
[3] Vall dHebron Hosp, Dept Internal Med, Barcelona, Spain
[4] Virgen del Rocio Hosp, Dept Hematol, Seville, Spain
[5] Reina Sofia Hosp, Dept Internal Med, Cordoba, Spain
[6] Univ Oviedo, Hosp Cent Asturias, Dept Hematol, E-33080 Oviedo, Spain
[7] Dr Negrin Hosp, Dept Med Oncol, Las Palmas Gran Canaria, Spain
[8] Infanta Cristina Hosp, Dept Internal Med, Badajoz, Spain
[9] Shire Pharmaceut Iber, Med Affairs, Madrid, Spain
[10] Hosp 12 Octubre, Dept Hematol, E-28041 Madrid, Spain
关键词
Type 1 Gaucher disease; Therapeutic goals; Bone disease; Spain; CLINICAL CHARACTERISTICS; STORAGE DISORDERS; REGISTRY; MANIFESTATIONS; COMPLICATIONS; DIAGNOSIS;
D O I
10.1016/j.bcmd.2015.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A multicentre, cross-sectional epidemiological survey was conducted to describe the health status of patients with type 1 Gaucher disease (GD1) in Spain. Patient data were collected retrospectively from clinical records. Therapeutic goals for seven clinical parameters were chosen as primary outcome measures. 108 GD1 patients (mean age 44.8 years; 53% male) were recruited from 28 hospitals. Ninety-five patients (88%) were receiving treatment for GD1. Hemoglobin concentration was the therapeutic goal with the highest level of achievement, being met by 105 of 108 patients (97%), followed by the goals for liver volume (86/98 patients; 88%), spleen volume (67/77 patients; 87%) and platelet count (81/108 patients; 75%). The goal for bone mineral density (BMD) was met by 48 of 75 patients (64%), and the goal for quality of life was met by 65 of 103 patients (63%). Bone pain was the parameter with the lowest level of achievement (goal met by 50/94 patients; 53%). The clinical information most often missing from patient records was the BMD Z-score (missing for 31% of patients). These data suggest that most Spanish GD1 patients have good control over hematological and visceral parameters, but there is a need to improve monitoring and treatment of GD-related bone disease. (C) 2015 Published by Elsevier Inc.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 23 条
[1]   Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies [J].
Aerts, Johannes M. F. G. ;
Kallemeijn, Wouter W. ;
Wegdam, Wouter ;
Ferraz, Maria Joao ;
van Breemen, Marielle J. ;
Dekker, Nick ;
Kramer, Gertjan ;
Poorthuis, Ben J. ;
Groener, Johanna E. M. ;
Cox-Brinkman, Josanne ;
Rombach, Saskia M. ;
Hollak, Carla E. M. ;
Linthorst, Gabor E. ;
Witte, Martin D. ;
Gold, Henrik ;
van der Marel, Gijs A. ;
Overkleeft, Herman S. ;
Boot, Rolf G. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 (03) :605-619
[2]  
ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771
[3]   Type 1 Gaucher Disease Significant Disease Manifestations in "Asymptomatic" Homozygotes [J].
Balwani, Manisha ;
Fuerstman, Laura ;
Kornreich, Ruth ;
Edelmann, Lisa ;
Desnick, Robert J. .
ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (16) :1463-1469
[4]  
Beutler E, 2001, Gaucher diseases
[5]   'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature [J].
Biegstraaten, M. ;
van Schaik, I. N. ;
Aerts, J. M. F. G. ;
Hollak, C. E. M. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 (03) :337-349
[6]   Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention [J].
Boot, RG ;
Verhoek, M ;
de Fost, M ;
Hollak, CEM ;
Maas, M ;
Bleijlevens, B ;
van Breemen, MJ ;
van Meurs, M ;
Boven, LA ;
Laman, JD ;
Moran, MT ;
Cox, TM ;
Aerts, JMFG .
BLOOD, 2004, 103 (01) :33-39
[7]   METABOLISM OF GLUCOCEREBROSIDES .2. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHERS DISEASE [J].
BRADY, RO ;
KANFER, JN ;
SHAPIRO, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1965, 18 (02) :221-&
[8]   The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease [J].
Charrow, J ;
Andersson, HC ;
Kaplan, P ;
Kolodny, EH ;
Mistry, P ;
Pastores, G ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ ;
Zimran, A .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (18) :2835-2843
[9]  
Drelichman G, 2012, MEDICINA-BUENOS AIRE, V72, P273
[10]   Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula [J].
Giraldo, Pilar ;
Alfonso, Pilar ;
Irun, Pilar ;
Gort, Laura ;
Chabas, Amparo ;
Vilageliu, Lluisa ;
Grinberg, Daniel ;
Sa Miranda, Clara M. ;
Pocovi, Miguel .
ORPHANET JOURNAL OF RARE DISEASES, 2012, 7